Jefferies raises Liquidia Technologies stock target to $31

On Tuesday, Jefferies analyst Kambiz Yazdi increased the price target for Liquidia Technologies (NASDAQ:LQDA) shares to $31.00, up from the previous target of $27.00, while reaffirming a Buy rating for the company’s stock. Currently trading at $15.82, LQDA has seen a 32% surge over the past six months, despite a recent 10% pullback last week. According to InvestingPro data, analyst targets for the stock range from $13 to $36, with a strong Buy consensus. Yazdi highlighted the recent approval of Yutrepia for the treatment of Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension in patients with Interstitial Lung Disease (PH-ILD).

The analyst noted the significance of Yutrepia’s label, which encompasses both indications and provides detailed dosing information, emphasizing its high titration capability. This feature is expected to be a key factor in communicating the drug’s benefits to healthcare providers and patients.

Liquidia is set to offer a comprehensive range of patient support services designed to facilitate a smooth initiation and transition to Yutrepia. Yazdi pointed out that Liquidia’s team possesses extensive experience and expertise in the cardiopulmonary field, which is anticipated to be beneficial in the drug’s market introduction and patient support.

The adjustment in Jefferies’ model, taking into account these recent developments, has led to an increase in the price target. The analyst reiterated a confident stance on Liquidia Technologies’ stock, maintaining a Buy rating and underscoring the company’s potential in the cardiopulmonary space with the introduction of Yutrepia.

In other recent news, Liquidia Technologies has received significant attention following the U.S. Food and Drug Administration’s (FDA) final approval of Yutrepia, a treatment for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Raymond (NSE:RYMD) James reaffirmed a Strong Buy rating with a $29 price target, highlighting the favorable tolerability shown in the ASCENT study for PH-ILD patients at higher doses. BTIG also maintained a Buy rating and a $29 target, noting Yutrepia’s unique position as the only approved Dry Powder Inhaler (DPI) treprostinil treatment with clinical data for these conditions. Scotiabank (TSX:BNS) reiterated a Sector Outperform rating with a $36 target, supported by promising ASCENT trial results presented at the American Thoracic Society (ATS) conference, which showed improvements in patient mobility and quality of life. Needham kept its Buy rating and a $25 target, emphasizing Yutrepia’s potential to improve treatment experiences for PAH and PH-ILD patients. The ongoing legal challenges from United Therapeutics (NASDAQ:UTHR) were described as increasingly weak by Raymond James, who noted that these are unlikely to affect Yutrepia’s market entry significantly. Liquidia has scheduled a webcast and a conference call to discuss commercial preparations, aiming to distribute Yutrepia within weeks of approval. The company is poised for the potential approval and launch of Yutrepia, marking a significant milestone in its strategy to address unmet needs in the PAH and PH-ILD markets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.